Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia

Highlights • Chronic lymphocytic leukemia (CLL) remains an incurable disease with conventional chemotherapy or chemoimmunotherapy. • Lenalidomide and rituximab is effective in heavily pretreated CLL. • Lenalidomide and rituximab has an acceptable toxicity profile in previously treated CLL.

Saved in:
Bibliographic Details
Published inLeukemia research Vol. 47; pp. 78 - 83
Main Authors Chavez, Julio C., MD, Piris-Villaespesa, Miguel, MD, Dalia, Samir, MD, Powers, John, PhD, Turba, Elyce, RN, Nodzon, Lisa, ARNP, Komrokji, Rami, MD, Sokol, Lubomir, PhD, Locke, Frederick L., MD, Lancet, Jeffrey, MD, Sotomayor, Eduardo M., MD, Kharfan-Dabaja, Mohamed A., MD, Pinilla-Ibarz, Javier, MD, PhD
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.08.2016
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - toxicity
CLL
Drug Administration Schedule
Female
Hematology, Oncology and Palliative Medicine
Humans
Infection - chemically induced
Lenalidomide
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - mortality
Male
Middle Aged
Neutropenia - chemically induced
Refractory
Remission Induction
Rituximab
Rituximab - administration & dosage
Salvage Therapy - methods
Salvage Therapy - mortality
Thalidomide - administration & dosage
Thalidomide - analogs & derivatives
Refractory
CLL
Lenalidomide
rituximab
Rituximab
Online AccessGet full text

Cover

More Information
Summary:Highlights • Chronic lymphocytic leukemia (CLL) remains an incurable disease with conventional chemotherapy or chemoimmunotherapy. • Lenalidomide and rituximab is effective in heavily pretreated CLL. • Lenalidomide and rituximab has an acceptable toxicity profile in previously treated CLL.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2016.05.012